December 06, 2016 4:56 PM ET


Company Overview of United Therapeutics Corporation

Company Overview

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s principal therapeutic products and product candidates include Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH); Tyvaso, an inhaled prostacyclin therapy for PAH; Adcirca, a once-daily oral therapy for PAH; Orenitram, a prostacyclin analog for PAH; Unituxin, an antibody that binds to cancerous tumors and destroys the cancer cells; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. ...

1040 Spring Street

Silver Spring, MD 20910

United States

Founded in 1996

750 Employees





Key Executives for United Therapeutics Corporation

Founder, Chairman of the Board and Chief Executive Officer
Age: 61
Total Annual Compensation: $1.1M
Chief Financial Officer and Treasurer
Age: 48
Total Annual Compensation: $380.1K
Executive Vice President of Strategic Planning, General Counsel and Corporate Secretary
Age: 52
Total Annual Compensation: $760.2K
Senior Advisor
Age: 54
Total Annual Compensation: $925.0K
Compensation as of Fiscal Year 2015.

United Therapeutics Corporation Key Developments

United Therapeutics Corporation Announces Consolidated Unaudited Earnings Results for the Third Quarter Ended September 30, 2016

United Therapeutics Corporation announced consolidated unaudited earnings results for the third quarter ended September 30, 2016. For the quarter, the company reported total revenues of $408.2 million compared with $386.2 million for the same period a year ago. Operating income was $238.6 million compared with $387.0 million for the same period a year ago. Income before income taxes was $239.1 million compared with $736.8 million for the same period a year ago. Net income was $161.8 million compared with $464.4 million for the same period a year ago. Net income per diluted share was $3.50 compared with $9.24 for the same period a year ago. Non-GAAP earnings was $201.5 million compared with $174.7 million for the same period a year ago. Non-GAAP earnings, per diluted share was $4.36 compared with $3.48 for the same period a year ago. Revenues for the three months ended September 30, 2016 increased by $22.0 million, compared to the same period in 2015. The growth in revenues primarily resulted from the following: a $22.2 million increase in Adcirca net product sales; a $12.6 million increase in Unituxin net product sales; a $6.3 million increase in Orenitram net product sales; and a $2.3 million increase in Remodulin net product sales. These increases were partially offset by a $19.9 million decrease in Tyvaso net product sales.

United Therapeutics Corporation to Report Q3, 2016 Results on Oct 27, 2016

United Therapeutics Corporation announced that they will report Q3, 2016 results at 9:00 AM, US Eastern Standard Time on Oct 27, 2016

United Therapeutics Corporation, Q3 2016 Earnings Call, Oct 27, 2016

United Therapeutics Corporation, Q3 2016 Earnings Call, Oct 27, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact United Therapeutics Corporation, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at